Accuryn Medical Company Profile

Background

Overview

Accuryn Medical, formerly known as Potrero Medical, is a privately held medical device company headquartered in Hayward, California. Established in 2011, the company specializes in developing innovative solutions for the early detection and management of Acute Kidney Injury (AKI) in critically ill patients. Their flagship product, the Accuryn® Monitoring System, transforms standard Foley catheters into advanced monitoring tools, enabling real-time assessment of urine output, intra-abdominal pressure, and core body temperature.

Mission and Vision

Accuryn Medical's mission is to enhance patient outcomes by providing clinicians with accurate, real-time data to support fluid management and kidney protection. Their vision is to revolutionize critical care through predictive health technologies, enabling earlier interventions and improved patient care.

Industry Significance

In the United States, approximately 300,000 patients die annually from AKI, highlighting the critical need for effective monitoring and early detection. Accuryn Medical addresses this challenge by offering a solution that allows clinicians to detect AKI up to 33 hours earlier than traditional methods, potentially reducing mortality and morbidity associated with the condition.

Key Strategic Focus

Core Objectives

Early Detection of AKI: Utilize advanced monitoring technologies to identify signs of AKI promptly, facilitating timely interventions.

Improved Patient Outcomes: Enhance patient care by providing clinicians with reliable data to inform treatment decisions.

Market Expansion: Broaden the adoption of the Accuryn Monitoring System across healthcare facilities to establish a standard of care for AKI detection.

Areas of Specialization

Critical Care Monitoring: Focus on monitoring vital signs in critically ill patients to prevent complications like AKI.

Predictive Health Technologies: Develop and implement technologies that predict adverse health events, enabling proactive care.

Key Technologies Utilized

SmartFoley Catheter: An advanced catheter that integrates sensors for continuous monitoring of urine output, intra-abdominal pressure, and core body temperature.

Active DrainLine Clearance: A patented technology that automates urine output monitoring, reducing manual estimation errors and improving data accuracy.

Primary Markets Targeted

Hospitals and Intensive Care Units (ICUs): Primary settings for the deployment of the Accuryn Monitoring System to monitor critically ill patients.

Nephrology Departments: Specialized units focusing on kidney care, where early detection of AKI is crucial.

Financials and Funding

Funding History

Accuryn Medical has raised a total of $79.68 million in funding over multiple rounds. The most recent funding round occurred approximately five months ago, raising $2.28 million.

Notable Investors

Specific details about individual investors are not publicly disclosed.

Utilization of Capital

The funds have been allocated towards:

Product Development: Enhancing the Accuryn Monitoring System and expanding the product portfolio.

Clinical Studies: Conducting research to validate the effectiveness of the monitoring system in various clinical settings.

Market Expansion: Increasing the adoption of the system across healthcare facilities.

Pipeline Development

Key Pipeline Candidates

AKI Detect Software: A software upgrade that detects oliguric AKI in accordance with KDIGO guidelines, providing early notification of kidney distress compared to standard serum creatinine tests.

Stages of Development

Clinical Validation: Ongoing studies to assess the accuracy and reliability of the AKI Detect software in diverse patient populations.

Target Conditions

Acute Kidney Injury (AKI): Focusing on early detection and management to prevent progression to more severe stages.

Anticipated Milestones

Regulatory Approvals: Seeking FDA clearance for new software features and expanded product indications.

Market Penetration: Achieving widespread adoption of the monitoring system in hospitals and ICUs.

Technological Platform and Innovation

Proprietary Technologies

SmartFoley Catheter: Transforms traditional Foley catheters into advanced monitoring devices with integrated sensors.

Active DrainLine Clearance: Ensures accurate urine output measurements by preventing backflow and airlocks.

Significant Scientific Methods

Predictive Analytics: Utilizes data from the monitoring system to predict adverse health events, enabling proactive interventions.

Real-Time Data Integration: Combines multiple physiological measurements to provide a comprehensive view of patient status.

Leadership Team

Executive Profiles

Todd Dunn – Chief Executive Officer (CEO): Leads the company with a focus on strategic growth and innovation in critical care monitoring.

Rich Keenan – Chief Product Officer (CPO): Oversees product development and ensures alignment with clinical needs and market demands.

Chris Schreiner – Executive Vice President of Sales: Drives sales strategies and partnerships to expand the company's market presence.

Ron Chavez – Vice President of Operations: Manages operational efficiency and scalability to support the company's growth initiatives.

Board of Directors

Chris Dewey – Executive Chairman: Provides strategic guidance and governance to the company.

Dr. Maurice Ferre, MD – Board Member: Offers medical expertise and insights into clinical applications of the company's technologies.

Ramachandra Reddy, MD – Board Member: Contributes knowledge in healthcare management and patient care strategies.

Mark Goldwasser – Board Member: Brings experience in financial management and business development.

Competitor Profile

Market Insights and Dynamics

The medical device industry, particularly in the realm of critical care monitoring, is experiencing significant growth due to increasing awareness of conditions like AKI and the need for early detection technologies. The market is characterized by rapid technological advancements and a focus on patient-centric solutions.

Competitor Analysis

Rockwell Medical (RMTI): Focuses on dialysis solutions and has a market capitalization of approximately $41.77 million.

Abbott Laboratories (ABT): A diversified healthcare company with a market capitalization of around $192.72 billion, offering a wide range of medical devices and diagnostics.

Intuitive Surgical (ISRG): Specializes in robotic-assisted surgical systems, with a market capitalization of about $173.36 billion.

Stryker (SYK): Provides a broad array of medical devices, including surgical instruments and implants, with a market capitalization of approximately $137.02 billion.

Medtronic (MDT): A global leader in medical technology, offering products across various medical disciplines, with a market capitalization of around $33.54 billion.

Strategic Collaborations and Partnerships

Accuryn Medical has engaged in strategic partnerships to enhance product development and market reach. Notably, they have collaborated with Medline Industries to expand their commercial business.

Operational Insights

Accuryn Medical differentiates itself through its focus on predictive health technologies and real-time monitoring solutions, addressing a critical gap in early AKI detection. Their proprietary technologies, such as the SmartFoley catheter and Active DrainLine Clearance, provide a competitive edge in the market.

Strategic Opportunities and Future Directions

The company aims to expand its product portfolio, enhance software capabilities, and increase market penetration to establish the Accuryn Monitoring System as a standard of care in critical care settings. Future directions include exploring international markets and developing additional predictive health solutions.